JP2024016014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016014A5 JP2024016014A5 JP2023145779A JP2023145779A JP2024016014A5 JP 2024016014 A5 JP2024016014 A5 JP 2024016014A5 JP 2023145779 A JP2023145779 A JP 2023145779A JP 2023145779 A JP2023145779 A JP 2023145779A JP 2024016014 A5 JP2024016014 A5 JP 2024016014A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063069408P | 2020-08-24 | 2020-08-24 | |
| US63/069,408 | 2020-08-24 | ||
| US202163142398P | 2021-01-27 | 2021-01-27 | |
| US63/142,398 | 2021-01-27 | ||
| JP2023513172A JP7349046B2 (ja) | 2020-08-24 | 2021-08-23 | Ｓａｒｍ１の阻害剤 |
| PCT/US2021/047093 WO2022046606A1 (en) | 2020-08-24 | 2021-08-23 | Inhibitors of sarm1 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513172A Division JP7349046B2 (ja) | 2020-08-24 | 2021-08-23 | Ｓａｒｍ１の阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024016014A JP2024016014A (ja) | 2024-02-06 |
| JP2024016014A5 true JP2024016014A5 (enExample) | 2024-08-30 |
| JP7756130B2 JP7756130B2 (ja) | 2025-10-17 |
Family
ID=77775005
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513172A Active JP7349046B2 (ja) | 2020-08-24 | 2021-08-23 | Ｓａｒｍ１の阻害剤 |
| JP2023145779A Active JP7756130B2 (ja) | 2020-08-24 | 2023-09-08 | Ｓａｒｍ１の阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513172A Active JP7349046B2 (ja) | 2020-08-24 | 2021-08-23 | Ｓａｒｍ１の阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12043613B2 (enExample) |
| EP (1) | EP4200293A1 (enExample) |
| JP (2) | JP7349046B2 (enExample) |
| KR (2) | KR20260016617A (enExample) |
| AU (2) | AU2021333558C1 (enExample) |
| BR (1) | BR112023002575A2 (enExample) |
| CA (1) | CA3189181A1 (enExample) |
| CL (1) | CL2023000525A1 (enExample) |
| CO (1) | CO2023001975A2 (enExample) |
| CR (1) | CR20230113A (enExample) |
| DO (1) | DOP2023000038A (enExample) |
| EC (1) | ECSP23012981A (enExample) |
| IL (1) | IL300586A (enExample) |
| MX (1) | MX2023002256A (enExample) |
| PE (1) | PE20230737A1 (enExample) |
| TW (3) | TWI904906B (enExample) |
| WO (1) | WO2022046606A1 (enExample) |
| ZA (1) | ZA202301801B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3123215C (en) | 2018-12-19 | 2024-04-02 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with neuroprotective agents |
| US12404265B2 (en) | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| EP4214197A1 (en) | 2020-09-16 | 2023-07-26 | Nura Bio, Inc. | Substituted pyridine derivatives as sarm1 inhibitors |
| KR20240041987A (ko) | 2021-07-28 | 2024-04-01 | 누라 바이오, 인크. | Sarm1 억제제로서 치환된 피리딘 유도체 |
| EP4558148A2 (en) * | 2022-07-21 | 2025-05-28 | Amylyx Pharmaceuticals Inc. | Oligonucleotide compositions and methods thereof |
| EP4634156A1 (en) * | 2022-12-15 | 2025-10-22 | Sironax Ltd | Sarm1 modulators, preparations, and uses thereof |
| EP4655069A1 (en) | 2023-01-24 | 2025-12-03 | Disarm Therapeutics, Inc. | Pyridazines as sarm1 inhibitors |
| EP4702017A1 (en) * | 2023-04-27 | 2026-03-04 | Sironax Ltd | Sarm1 modulators, preparations, and uses thereof |
| CN119219603A (zh) * | 2023-06-28 | 2024-12-31 | 科辉智药(深圳)新药研究中心有限公司 | Sarm1酶活性抑制剂及其用途 |
| AU2024332440A1 (en) | 2023-08-25 | 2026-03-12 | Eli Lilly And Company | (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate |
| WO2025045746A1 (en) * | 2023-08-25 | 2025-03-06 | F. Hoffmann-La Roche Ag | Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders |
| WO2025076017A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Carbamates for use as sarm1 inhibitors |
| WO2025076088A1 (en) * | 2023-10-05 | 2025-04-10 | Genentech, Inc. | Lactams for use as sarm1 inhibitors |
| WO2025157895A1 (en) | 2024-01-25 | 2025-07-31 | UCB Biopharma SRL | Pyrrolidinone derivatives |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE257703T1 (de) | 1997-10-27 | 2004-01-15 | Takeda Chemical Industries Ltd | 1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes |
| US6787555B2 (en) | 2001-04-30 | 2004-09-07 | The Procter & Gamble Company | Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| JP2006514684A (ja) | 2002-10-30 | 2006-05-11 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物 |
| EP1581222A2 (en) | 2003-01-02 | 2005-10-05 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr; |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| US7585881B2 (en) | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| DE602005020611D1 (de) | 2004-04-28 | 2010-05-27 | Vertex Pharma | Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen |
| EP1831168B1 (en) | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. |
| JP5244591B2 (ja) | 2006-06-28 | 2013-07-24 | あすか製薬株式会社 | ピリジルイソオキサゾール誘導体 |
| JP2010504295A (ja) | 2006-09-21 | 2010-02-12 | ノバルティス アーゲー | サイトカイン介在疾患の処置に有用なピロール誘導体 |
| EP2238134A2 (en) | 2007-12-20 | 2010-10-13 | Novartis AG | Bis-thiazole derivatives, process for their preparation and their use as medicaments |
| BRPI0820722A2 (pt) | 2007-12-20 | 2015-06-16 | Novartis Ag | Derivados de tiazol usados como inibidores de pi 3 cinases |
| TW201004941A (en) | 2008-07-16 | 2010-02-01 | Wyeth Corp | Alpha7 nicotinic acetylcholine receptor inhibitors |
| US8785468B2 (en) | 2009-02-13 | 2014-07-22 | Amgen Inc. | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions |
| US20120328629A1 (en) | 2011-06-24 | 2012-12-27 | University Of Miami | Therapeutic Applications Targeting SARM1 |
| WO2014070978A1 (en) | 2012-11-03 | 2014-05-08 | Boehringer Ingelheim International Gmbh | Inhibitors of cytomegalovirus |
| WO2014099694A1 (en) | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| RU2570907C2 (ru) | 2013-10-21 | 2015-12-20 | Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" | Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа. |
| EP3076789A4 (en) | 2013-12-04 | 2017-11-22 | The Scripps Research Institute | Novel compounds as jnk kinase inhibitors |
| US11357800B2 (en) | 2016-08-16 | 2022-06-14 | Henry Ford Health System | Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies |
| JP7044789B2 (ja) * | 2016-09-24 | 2022-03-30 | ワシントン・ユニバーシティ | Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用 |
| US20180251431A1 (en) | 2016-12-09 | 2018-09-06 | Vertex Pharmaceuticals Incorporated | 1,3-substituted pyrazole compounds useful for reduction of very long chain fatty acid levels |
| EP3558986A1 (de) * | 2016-12-22 | 2019-10-30 | Bayer CropScience Aktiengesellschaft | Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe |
| JP2020504115A (ja) | 2016-12-22 | 2020-02-06 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 置換アゾリルピロロンおよびアゾリルヒダントインならびにその塩ならびに除草活性物質としてのその使用 |
| AU2018388406B2 (en) * | 2017-12-22 | 2023-07-06 | HiberCell Inc. | Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2019236884A1 (en) | 2018-06-07 | 2019-12-12 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| CN120398784A (zh) * | 2018-06-07 | 2025-08-01 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CN112839647B (zh) | 2018-06-07 | 2025-09-23 | 达萨玛治疗公司 | Sarm1抑制剂 |
| EP3919055A4 (en) | 2019-01-30 | 2022-11-09 | Takeda Pharmaceutical Company Limited | HETEROCYCLIC COMPOUND |
| CA3140578C (en) | 2019-06-06 | 2025-06-17 | Disarm Therapeutics, Inc. | SARM1 INHIBITORS |
| CA3141404A1 (en) | 2019-06-14 | 2020-12-17 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| UY38795A (es) | 2019-07-22 | 2021-02-26 | Bayer Ag | 5-amino pirazoles y triazoles como plaguicidas |
| EP4028013A4 (en) | 2019-09-12 | 2023-10-18 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS |
| EP4054554A1 (en) | 2019-11-05 | 2022-09-14 | Dermira, Inc | Mrgprx2 antagonists for the treatment of inflammatory disorders |
| JP7490781B2 (ja) | 2020-01-07 | 2024-05-27 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| EP4132928B1 (en) | 2020-04-09 | 2025-12-24 | Disarm Therapeutics, Inc. | Condensed pyrazole derivatives as inhibitors of sarm1 |
| EP4132920B1 (en) | 2020-04-09 | 2025-08-13 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
| US12404265B2 (en) * | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
-
2021
- 2021-08-20 TW TW113140249A patent/TWI904906B/zh active
- 2021-08-20 TW TW111144632A patent/TW202334117A/zh unknown
- 2021-08-20 TW TW110130799A patent/TWI786777B/zh active
- 2021-08-23 WO PCT/US2021/047093 patent/WO2022046606A1/en not_active Ceased
- 2021-08-23 MX MX2023002256A patent/MX2023002256A/es unknown
- 2021-08-23 EP EP21770372.7A patent/EP4200293A1/en active Pending
- 2021-08-23 BR BR112023002575A patent/BR112023002575A2/pt unknown
- 2021-08-23 JP JP2023513172A patent/JP7349046B2/ja active Active
- 2021-08-23 CR CR20230113A patent/CR20230113A/es unknown
- 2021-08-23 AU AU2021333558A patent/AU2021333558C1/en active Active
- 2021-08-23 PE PE2023000530A patent/PE20230737A1/es unknown
- 2021-08-23 KR KR1020267002225A patent/KR20260016617A/ko active Pending
- 2021-08-23 US US17/408,956 patent/US12043613B2/en active Active
- 2021-08-23 IL IL300586A patent/IL300586A/en unknown
- 2021-08-23 KR KR1020237009643A patent/KR102918550B1/ko active Active
- 2021-08-23 CA CA3189181A patent/CA3189181A1/en active Pending
-
2023
- 2023-02-14 ZA ZA2023/01801A patent/ZA202301801B/en unknown
- 2023-02-22 CL CL2023000525A patent/CL2023000525A1/es unknown
- 2023-02-22 CO CONC2023/0001975A patent/CO2023001975A2/es unknown
- 2023-02-23 EC ECSENADI202312981A patent/ECSP23012981A/es unknown
- 2023-02-23 DO DO2023000038A patent/DOP2023000038A/es unknown
- 2023-09-08 JP JP2023145779A patent/JP7756130B2/ja active Active
-
2024
- 2024-05-21 AU AU2024203373A patent/AU2024203373A1/en active Pending
- 2024-06-19 US US18/747,889 patent/US20240376083A1/en active Pending